Do analysts prefer TPCS or MYNZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Techprecision 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts recommend MYNZ or SYPR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Sypris Solutions 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend ZENA or MYNZ?

ZenaTech presently has a consensus price target of $4.50, indicating a potential upside of 110.28%. Given ZenaTech's stronger consensus rating and higher possible upside, research analysts plainly believe ZenaTech is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZenaTech 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is ZENA or MYNZ more profitable?

Mainz Biomed has a net margin of 0.00% compared to ZenaTech's net margin of -332.51%. Company Net Margins Return on Equity Return on Assets ZenaTech -332.51% N/A -78.90% Mainz Biomed N/A N/A N/A

Do analysts recommend VTSI or MYNZ?

VirTra currently has a consensus target price of $5.00, indicating a potential upside of 54.80%. Given VirTra's stronger consensus rating and higher possible upside, analysts plainly believe VirTra is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VirTra 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has stronger valuation and earnings, VTSI or MYNZ?

VirTra has higher revenue and earnings than Mainz Biomed. VirTra is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio VirTra $17.50M 2.09 $260K -$0.26 N/A Mainz Biomed $659.94K 20.25 -$21.65M -$65.60 N/A

Do analysts recommend VWAV or MYNZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VisionWave 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is VWAV or MYNZ more profitable?

Mainz Biomed's return on equity of 0.00% beat VisionWave's return on equity. Company Net Margins Return on Equity Return on Assets VisionWave N/A -119.11% -57.02% Mainz Biomed N/A N/A N/A

Mainz Biomed (MYNZ) Competitors

$1.48 +0.06 (+3.87%)

As of 08/14/2026

Compare

MYNZ vs. TPCS, SYPR, ZENA, VTSI, and VWAV

Should you buy Mainz Biomed stock or one of its competitors? Mainz Biomed's main competitors and comparable companies include Techprecision (TPCS), Sypris Solutions (SYPR), ZenaTech (ZENA), VirTra (VTSI), and VisionWave (VWAV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "aerospace & defense" industry.

How does Mainz Biomed compare to Techprecision?

Techprecision (NASDAQ:TPCS) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap industrials companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Techprecision has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

15.5% of Techprecision shares are owned by institutional investors. 15.3% of Techprecision shares are owned by insiders. Comparatively, 18.2% of Mainz Biomed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Techprecision has higher revenue and earnings than Mainz Biomed. Techprecision is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Techprecision	$31.64M	1.90	-$1.66M	-$0.17	N/A
Mainz Biomed	$659.94K	20.25	-$21.65M	-$65.60	N/A

In the previous week, Techprecision had 6 more articles in the media than Mainz Biomed. MarketBeat recorded 6 mentions for Techprecision and 0 mentions for Mainz Biomed. Techprecision's average media sentiment score of 0.40 beat Mainz Biomed's score of 0.00 indicating that Techprecision is being referred to more favorably in the media.

Company	Overall Sentiment
Techprecision	Neutral
Mainz Biomed	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Techprecision	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Mainz Biomed has a net margin of 0.00% compared to Techprecision's net margin of -3.66%. Mainz Biomed's return on equity of 0.00% beat Techprecision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Techprecision	-3.66%	-14.78%	-3.70%
Mainz Biomed	N/A	N/A	N/A

Summary

Techprecision and Mainz Biomed tied by winning 7 of the 14 factors compared between the two stocks.

How does Mainz Biomed compare to Sypris Solutions?

Mainz Biomed (NASDAQ:MYNZ) and Sypris Solutions (NASDAQ:SYPR) are both small-cap industrials companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Sypris Solutions has higher revenue and earnings than Mainz Biomed. Sypris Solutions is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$659.94K	20.25	-$21.65M	-$65.60	N/A
Sypris Solutions	$116.19M	0.41	-$6.34M	-$0.42	N/A

Mainz Biomed has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, Sypris Solutions has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

44.7% of Sypris Solutions shares are held by institutional investors. 18.2% of Mainz Biomed shares are held by company insiders. Comparatively, 47.9% of Sypris Solutions shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Sypris Solutions had 3 more articles in the media than Mainz Biomed. MarketBeat recorded 3 mentions for Sypris Solutions and 0 mentions for Mainz Biomed. Sypris Solutions' average media sentiment score of 0.44 beat Mainz Biomed's score of 0.00 indicating that Sypris Solutions is being referred to more favorably in the news media.

Company	Overall Sentiment
Mainz Biomed	Neutral
Sypris Solutions	Neutral

Mainz Biomed has a net margin of 0.00% compared to Sypris Solutions' net margin of -8.23%. Mainz Biomed's return on equity of 0.00% beat Sypris Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
Sypris Solutions	-8.23%	-54.45%	-8.87%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Sypris Solutions	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Sypris Solutions beats Mainz Biomed on 8 of the 14 factors compared between the two stocks.

How does Mainz Biomed compare to ZenaTech?

ZenaTech (NASDAQ:ZENA) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap industrials companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

In the previous week, ZenaTech had 9 more articles in the media than Mainz Biomed. MarketBeat recorded 9 mentions for ZenaTech and 0 mentions for Mainz Biomed. ZenaTech's average media sentiment score of 0.43 beat Mainz Biomed's score of 0.00 indicating that ZenaTech is being referred to more favorably in the media.

Company	Overall Sentiment
ZenaTech	Neutral
Mainz Biomed	Neutral

Mainz Biomed has a net margin of 0.00% compared to ZenaTech's net margin of -332.51%.

Company	Net Margins	Return on Equity	Return on Assets
ZenaTech	-332.51%	N/A	-78.90%
Mainz Biomed	N/A	N/A	N/A

ZenaTech has a beta of 7.14, suggesting that its share price is 614% more volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

Mainz Biomed has lower revenue, but higher earnings than ZenaTech. ZenaTech is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZenaTech	$9.24M	5.21	-$32.36M	-$1.42	N/A
Mainz Biomed	$659.94K	20.25	-$21.65M	-$65.60	N/A

ZenaTech presently has a consensus price target of $4.50, indicating a potential upside of 110.28%. Given ZenaTech's stronger consensus rating and higher possible upside, research analysts plainly believe ZenaTech is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZenaTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

ZenaTech beats Mainz Biomed on 8 of the 13 factors compared between the two stocks.

How does Mainz Biomed compare to VirTra?

VirTra (NASDAQ:VTSI) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap industrials companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

Mainz Biomed has a net margin of 0.00% compared to VirTra's net margin of -17.04%. Mainz Biomed's return on equity of 0.00% beat VirTra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VirTra	-17.04%	-6.54%	-4.59%
Mainz Biomed	N/A	N/A	N/A

VirTra currently has a consensus target price of $5.00, indicating a potential upside of 54.80%. Given VirTra's stronger consensus rating and higher possible upside, analysts plainly believe VirTra is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VirTra	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

14.7% of VirTra shares are held by institutional investors. 3.5% of VirTra shares are held by insiders. Comparatively, 18.2% of Mainz Biomed shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

VirTra has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market.

In the previous week, VirTra had 6 more articles in the media than Mainz Biomed. MarketBeat recorded 6 mentions for VirTra and 0 mentions for Mainz Biomed. VirTra's average media sentiment score of 0.83 beat Mainz Biomed's score of 0.00 indicating that VirTra is being referred to more favorably in the media.

Company	Overall Sentiment
VirTra	Positive
Mainz Biomed	Neutral

VirTra has higher revenue and earnings than Mainz Biomed. VirTra is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VirTra	$17.50M	2.09	$260K	-$0.26	N/A
Mainz Biomed	$659.94K	20.25	-$21.65M	-$65.60	N/A

Summary

VirTra beats Mainz Biomed on 10 of the 16 factors compared between the two stocks.

How does Mainz Biomed compare to VisionWave?

VisionWave (NASDAQ:VWAV) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap industrials companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

51.4% of VisionWave shares are owned by institutional investors. 12.6% of VisionWave shares are owned by insiders. Comparatively, 18.2% of Mainz Biomed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VisionWave	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, VisionWave had 2 more articles in the media than Mainz Biomed. MarketBeat recorded 2 mentions for VisionWave and 0 mentions for Mainz Biomed. VisionWave's average media sentiment score of 0.94 beat Mainz Biomed's score of 0.00 indicating that VisionWave is being referred to more favorably in the media.

Company	Overall Sentiment
VisionWave	Positive
Mainz Biomed	Neutral

VisionWave has higher earnings, but lower revenue than Mainz Biomed. VisionWave is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VisionWave	N/A	N/A	-$6.55M	-$1.29	N/A
Mainz Biomed	$659.94K	20.25	-$21.65M	-$65.60	N/A

VisionWave has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

Mainz Biomed's return on equity of 0.00% beat VisionWave's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VisionWave	N/A	-119.11%	-57.02%
Mainz Biomed	N/A	N/A	N/A

Summary

VisionWave and Mainz Biomed tied by winning 6 of the 12 factors compared between the two stocks.

Get Mainz Biomed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MYNZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MYNZ vs. The Competition

Export

Metric	Mainz Biomed	Aerospace & Defense Industry	Industrials Sector	NASDAQ Exchange
Market Cap	$13.36M	$23.45B	$10.95B	$13.06B
Dividend Yield	N/A	1.60%	97.10%	10.44%
P/E Ratio	-0.02	44.39	27.86	25.28
Price / Sales	20.25	165.28	333.34	75.26
Price / Cash	N/A	30.29	24.95	50.90
Price / Book	0.57	8.51	4.78	6.24
Net Income	-$21.65M	$562.35M	$609.43M	$347.60M
7 Day Performance	2.43%	3.39%	0.78%	1.06%
1 Month Performance	17.06%	12.79%	3.00%	0.81%
1 Year Performance	-16.67%	27.12%	14.45%	20.90%

Mainz Biomed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MYNZ Mainz Biomed	N/A	$1.48 +3.9%	N/A	-16.0%	$13.36M	$659.94K	N/A	30	High Trading Volume
TPCS Techprecision	0.3323 of 5 stars	$4.85 -0.2%	N/A	+18.6%	$48.60M	$31.64M	N/A	160	News Coverage Earnings Report Gap Up
SYPR Sypris Solutions	0.4219 of 5 stars	$2.09 +2.2%	N/A	+4.6%	$47.98M	$119.89M	N/A	680	Short Interest Increase
ZENA ZenaTech	3.339 of 5 stars	$1.82 +6.4%	$4.50 +147.3%	-58.6%	$40.95M	$9.24M	N/A	11	Analyst Downgrade High Trading Volume
VTSI VirTra	4.0049 of 5 stars	$3.15 +3.3%	$5.00 +58.7%	-38.2%	$35.63M	$22.40M	N/A	120	News Coverage Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MYNZ) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mainz Biomed (MYNZ) Competitors

MYNZ vs. TPCS, SYPR, ZENA, VTSI, and VWAV

How does Mainz Biomed compare to Techprecision?

Summary

How does Mainz Biomed compare to Sypris Solutions?

Summary

How does Mainz Biomed compare to ZenaTech?

Summary

How does Mainz Biomed compare to VirTra?

Summary

How does Mainz Biomed compare to VisionWave?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYNZ vs. The Competition

Mainz Biomed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mainz Biomed (MYNZ) Competitors

MYNZ vs. TPCS, SYPR, ZENA, VTSI, and VWAV

How does Mainz Biomed compare to Techprecision?

Which has more risk and volatility, TPCS or MYNZ?

Do institutionals and insiders hold more shares of TPCS or MYNZ?

Which has better valuation and earnings, TPCS or MYNZ?

Does the media refer more to TPCS or MYNZ?

Do analysts prefer TPCS or MYNZ?

Is TPCS or MYNZ more profitable?

Summary

How does Mainz Biomed compare to Sypris Solutions?

Which has stronger earnings & valuation, MYNZ or SYPR?

Which has more volatility and risk, MYNZ or SYPR?

Do institutionals & insiders hold more shares of MYNZ or SYPR?

Does the media prefer MYNZ or SYPR?

Is MYNZ or SYPR more profitable?

Do analysts recommend MYNZ or SYPR?

Summary

How does Mainz Biomed compare to ZenaTech?

Does the media refer more to ZENA or MYNZ?

Is ZENA or MYNZ more profitable?

Which has more volatility and risk, ZENA or MYNZ?

Which has preferable earnings and valuation, ZENA or MYNZ?

Do analysts recommend ZENA or MYNZ?

Summary

How does Mainz Biomed compare to VirTra?

Is VTSI or MYNZ more profitable?

Do analysts recommend VTSI or MYNZ?

Do insiders and institutionals believe in VTSI or MYNZ?

Which has more volatility & risk, VTSI or MYNZ?

Does the media refer more to VTSI or MYNZ?

Which has stronger valuation and earnings, VTSI or MYNZ?

Summary

How does Mainz Biomed compare to VisionWave?

Do institutionals & insiders have more ownership in VWAV or MYNZ?

Do analysts recommend VWAV or MYNZ?

Does the media favor VWAV or MYNZ?

Which has preferable valuation & earnings, VWAV or MYNZ?

Which has more risk and volatility, VWAV or MYNZ?

Is VWAV or MYNZ more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYNZ vs. The Competition

Mainz Biomed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools